$12.76
+0.25 (+2.00%)
Open$12.61
Previous Close$12.51
Day High$12.87
Day Low$12.40
52W High$17.32
52W Low$2.67
Volume—
Avg Volume3.39M
Market Cap2.40B
P/E Ratio—
EPS$-1.61
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+411.2% upside
Current
$12.76
$12.76
Target
$65.23
$65.23
$47.67
$65.23 avg
$99.61
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 16.81M | 8.30M | 220.69M |
| Net Income | -302,654,545 | -252,156,044 | 45.13M |
| Profit Margin | -1,800.6% | -3,206.0% | 20.5% |
| EBITDA | -328,350,034 | -289,236,526 | 96.01M |
| Free Cash Flow | — | — | 41.24M |
| Rev Growth | +123.3% | +48.9% | +11.7% |
| Debt/Equity | — | — | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |